胺碘酮肺损伤的临床特点及治疗预后

中华养生保健 ›› 2024, Vol. 42 ›› Issue (3): 1-4.

• 论著 • 下一篇

胺碘酮肺损伤的临床特点及治疗预后

张森森^1,2,3,4, 张纳新^1,2,3,4

1.天津市第三中心医院呼吸科,天津,300170;
2.天津市重症疾病体外生命支持重点实验室,天津,300170;
3.天津市人工细胞工程技术研究中心,天津,300170;
4.天津市肝胆疾病研究所,天津,300170

出版日期:2024-02-01 发布日期:2024-01-23
作者简介:张森森（1987—）,女,汉族,籍贯：河北省唐山市,硕士研究生,主治医师,研究方向：中西医诊治呼吸系统疾病。

The Clinical Feature and Treatment Prognosis of Amiodarone-Induced Pulmonary Toxicity

ZHANG Sen-sen^1,2,3,4, ZHANG Na-xin^1,2,3,4

1. Department of Respiratory Medicine, The Third Central Hospital of Tianjin, Tianjin 300170, China;
2. Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Tianjin 300170, China;
3. Artifical Cell Engineering Technology Research Center, Tianjin 300170, China;
4. Tianjin Institute of Hepatobiliary Disease, Tianjin 300170, China

Online:2024-02-01 Published:2024-01-23

摘要/Abstract

摘要： 目的胺碘酮是最常用的抗心律失常药物,间质性肺炎是其严重不良反应,本研究探讨胺碘酮致弥漫性间质性肺炎的临床特点及治疗预后。方法回顾性分析1例胺碘酮致弥漫性间质性肺炎的临床表现、影像特点、治疗及转归。结果本研究1例高龄男性患者,使用胺碘酮1.5个月后出现咳嗽、呼吸困难,病程发展迅速,快速出现Ⅰ型呼吸衰竭,经对症处理、停用胺碘酮、给予无创呼吸机辅助呼吸、激素等治疗后,临床症状消失。结论胺碘酮致弥漫性间质性肺炎的诊断应根据用药史、结合临床及影像学表现。治疗中应及时停用胺碘酮,对重症患者给予激素、呼吸机的使用是治疗成功的关键。

关键词: 胺碘酮, 间质性肺炎, 胺碘酮肺损伤

Abstract: Objective Amiodarone is the most commonly used antiarrhythmic drug, and interstitial pneumonia is its serious adverse reaction. This study aims to explore the clinical feature and treatment prognosis of amiodarone-induced diffuse interstitial pneumonia. Methods A case of amiodarone-induced diffuse interstitial pneumonia was retrospectively analyzed in terms of clinical manifestations, imaging feature, treatment and outcome. Results The elderly male patient appeared to have symptoms of cough, dyspnea after use of amiodarone for 1.5 months. The course of disease develops rapidly, followed by type Ⅰ respiratory failure. After symptomatic treatment, withdrawal of amiodarone, non-invasive ventilator assisted breathing, administration of hormones, the clinical symptoms disappeared. Conclusion The diagnosis of amiodarone-induced diffuse interstitial pneumonia should be based on medication history, combined with clinical and imaging findings. The key to successful treatment is to discontinue amiodarone, give corticosteroid and ventilator therapy in severe patients.

Key words: amiodarone, interstitial pneumonia, amiodarone-induced pulmonary toxicity

中图分类号:

R563.1

张森森, 张纳新. 胺碘酮肺损伤的临床特点及治疗预后[J]. 中华养生保健, 2024, 42(3): 1-4.

ZHANG Sen-sen, ZHANG Na-xin. The Clinical Feature and Treatment Prognosis of Amiodarone-Induced Pulmonary Toxicity[J]. ZHONGHUA YANGSHENG BAOJIAN, 2024, 42(3): 1-4.

参考文献

[1] 陆宇华,赵婷婷,张彤彤,等.胺碘酮临床不良反应及其预防措施的研究进展[J].中国药物滥用防治杂志,2022,28(4):409-412.
[2] SATO N, KOJIMA K, HORIO Y, et al.Successful treatment of severe amiodarone pulmonary toxicity with polymyxin B-immobilized fiber column direct hemoperfusion[J]. Chest,2013,143(4):1146-1150.
[3] KARINAUSKE E, ABRAMAVICIUS S, MUSTEIKIENE,G, et al.A case report and literature review: previously excluded tuberculosis masked by amiodarone induced lung injury[J]. BMC Pharmacol Toxicol,2018,19(1):88.
[4] RODEN A C, CAMUS P.Latrogenic pulmonary lesions[J]. Semin Diagn Pathol, 2018,35(4):260-271.
[5] MATSUMOTO K, NAKAO S, HASEGAWA S, et al.Analysis of drug-induced interstitial lung disease using the Japanese adverse drug event report database[J]. SAGE Open Med,2020,8:2050312120918264.
[6] SKEOCH S, WEATHERLEY N, SWIFT A J, et al.Drug-Induced Interstitial Lung Disease: A Systematic Review[J]. J Clin Med,2018,7(10):356.
[7] 刘晓园,秦又发,邓涛.1例胺碘酮致间质性肺炎的病例分析及相关文献复习[J].中国当代医药,2019,26(36):223-225.
[8] 韩雪,张凤全,霍健伟,等.胺碘酮肺毒性的CT表现[J].中国医学装备,2018,15(12):79-81.
[9] TERZO F, RICCI A, D’ASCANIO M, et al. Amiodarone-induced pulmonary toxicity with an excellent response to treatment: A case report[J]. Respir Med Case Rep,2019,29:100974.
[10] 盛海燕,冯瑞娥,胥杰,等.胺碘酮肺部不良反应二例[J].中华结核和呼吸杂志,2020,43(11):977-980.
[11] SCARAMOZZINO M U, SAPONE G, PLASTINA U R, et al.Amiodarone-induced lung toxicity: A case initially not correctly framed[J]. Cureus,2023,15(3):e36818.
[12] KINOSHITA S, HOSOMI K, YOKOYAMA S, et al.Inverse association between metformin and amiodarone-associated extracardiac adverse events[J]. Int J Med Sci,2020,17(3):302-309.
[13] HARB I, ASHOUR H, RASHED L A, et al.Nicorandil mitigates amiodarone-induced pulmonary toxicity and fibrosis in association with the inhibition of lung TGF-β1/PI3K/Akt1-p/mTOR axis in rats[J]. Clin Exp Pharmacol Physiol,2023,50(1):96-106.
[14] METER M, PRUSAC I K, GLAVAŠ D, et al.Acute respiratory failure on a low dose of amiodarone-is it an underdiagnosed and undertreated condition?[J]. Respir Med Case Rep,2021,34:101500.
[15] FEDUSKA E T, THOMA B N, TORJMAN M C, et al.Acute amiodarone pulmonary toxicity[J]. J Cardiothorac Vasc Anesth,2021,35(5):1485-1494.

胺碘酮肺损伤的临床特点及治疗预后

The Clinical Feature and Treatment Prognosis of Amiodarone-Induced Pulmonary Toxicity

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 14

编辑推荐

Metrics

本文评价

[1]	杨柳. 胺碘酮与西地兰治疗急诊危重症合并急性快速型心房颤动的效果对比[J]. 中华养生保健, 2023, 41(9): 170-172.
[2]	李敏辉. 胺碘酮在抢救心力衰竭伴快速心房颤动患者中的疗效探讨[J]. 中华养生保健, 2023, 41(1): 91-93.
[3]	陈永明. 胺碘酮在急诊冠心病合并快速心律失常治疗中的有效性及可行性探究[J]. 中华养生保健, 2022, 40(9): 52-55.
[4]	华明磊, 刘晓敏, 薛婧. 低分子肝素联合乙酰半胱氨酸治疗特发性间质性肺炎的疗效[J]. 中华养生保健, 2022, 40(6): 1-4.
[5]	马玉洁. 美托洛尔联合胺碘酮在冠心病心律不齐患者中的治疗效果[J]. 中华养生保健, 2022, 40(5): 157-159.
[6]	王艳. 胺碘酮联合倍他乐克急诊治疗室性心律失常对患者心动过速发作次数的改善探讨[J]. 中华养生保健, 2022, 40(4): 139-142.
[7]	马丽娜, 孟婷, 蒋庆军, 李伏, 席少静. 伊布利特和胺碘酮在永久性心脏起搏器植入术后新发心房颤动中的应用疗效和安全性对比[J]. 中华养生保健, 2022, 40(22): 56-59.
[8]	贺海彪, 魏萍, 孙兆艳, 刘册家. 肺毒性药物诱导肺泡上皮细胞损伤作用的研究进展[J]. 中华养生保健, 2022, 40(17): 64-66.
[9]	刘江波. 分析院前急救中选择胺碘酮与盐酸普罗帕酮治疗阵发性室上性心动过速的临床疗效对比[J]. 中华养生保健, 2022, 40(16): 57-60.
[10]	孟玲丽，朱英娟，王春红. 胺碘酮联合美托洛尔治疗快速心律失常的临床效果及不良反应发生率分析[J]. 中华养生保健, 2021, 39(1): 165-167.
[11]	孟静，邹剑峰. 胺碘酮治疗心力衰竭伴快速房颤的短时效果分析[J]. 中华养生保健, 2021, 39(1): 190-191.
[12]	张亚江. 观察胺碘酮治疗心律失常患者的临床效果[J]. 中华养生保健, 2020, 38(5): 181-182.
[13]	隋薇. 卡维地洛+胺碘酮治疗心律失常的效果观察及超敏C反应蛋白水平影响分析[J]. 中华养生保健, 2020, 38(3): 195-196.
[14]	张云珊, 田伟盟. 胺碘酮联合美托洛尔用于冠心病心律失常临床治疗效果观察[J]. 中华养生保健, 2020, 38(2): 90-92.